Skip to main content

What Insulet's latest 10-Q says: 5 signals

Insulet filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses capacity constraint, capex increase and market expansion.

Public (PODD)Medical Equipment Manufacturing1,001 to 5,000 employeesinsulet.comLinkedIn

10-Q · latest 10

What Insulet's 10-Q filings say

  1. 10-Q

    Filed · 5 signals

    SEC EDGAR
  2. 10-Q

    Filed · 11 signals

    SEC EDGAR

Showing 10 of 16 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Insulet earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Announced meaningful increase in CapEx for manufacturing expansionLeadership is accelerating investments to increase capacity at its manufacturing facilities to support a strong growth trajectory. This creates opportunities for vendors in construction, industrial automation, equipment, and supply chain management.
Appointed new CFO, COO, and created new Chief Growth Officer roleA major C-suite refresh includes a new CFO (Flavia Pease), a promoted COO (Eric Benjamin), and a new CGO (Manoj Raghunandanan), signaling potential shifts in financial, operational, and growth strategies that often trigger vendor reviews.
Integrating AI and cloud-based tools to scale service operationsThe company is actively integrating AI and cloud technologies to streamline and efficiently scale its customer service operations. This points to active projects and budget for AI/ML platforms, cloud infrastructure, and customer service automation solutions.
Expanding sales, commercial, and customer experience teamsThe company is actively hiring to expand its sales force and customer-facing teams to drive market penetration and support a growing customer base. This signals needs for HR tech, recruiting services, sales enablement tools, and CRM solutions.
Actively addressing friction in the prior authorization submission processLeadership identified the prior authorization process as a key barrier to patient access and is implementing targeted programs to ease submissions. This creates an opportunity for vendors specializing in healthcare workflow automation and patient access solutions.
Achieved record new customer starts globally, with Type 2 doublingThe company is experiencing unprecedented customer acquisition, particularly in the U.S. Type 2 market where new starts doubled year-over-year. This rapid scaling requires robust systems for customer onboarding, support, data management, and engagement.

Signal API · MCP

Track Insulet with the Signal API

One POST /v1/companies/enrich call with insulet.com returns Insulet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"insulet.com","signal_types":["sec-10q"],"limit":20}'

Same industry

Questions about Insulet 10-Q

When did Insulet file its latest 10-Q?
Insulet filed its latest 10-Q on Aug 5, 2026. The one before it was filed on May 6, 2026.
What did Insulet disclose in its latest 10-Q?
From the filing dated Aug 5, 2026: CapEx up 84% to $56.8M for new Costa Rica plant and manufacturing expansion.
What did Insulet say on its recent earnings calls?
Q3 FY2025: Announced meaningful increase in CapEx for manufacturing expansion (dated Nov 6, 2025).
Where can I read Insulet's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000169/podd-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →